Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 19Carcinoma, Hepatocellular 8Squamous Cell Carcinoma of Head and Neck 7Melanoma 7Lung Neoplasms 5Neoplasms 4Neoplasm Metastasis 4Esophageal Neoplasms 4Uterine Cervical Neoplasms 3Rectal Neoplasms 3Head and Neck Neoplasms 3Esophageal Squamous Cell Carcinoma 3Triple Negative Breast Neoplasms 2Recurrence 2Pathologic Complete Response 2Pancreatic Neoplasms 2Neoplasm, Residual 2Hyperthermia 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Breast Neoplasms 2Brain Neoplasms 2Uveal Melanoma 1Turcot syndrome 1Small Cell Lung Carcinoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Radiation Pneumonitis 1

Interventions

anlotinib 1Radiotherapy 1Immunotherapy 1Drug Therapy 1Docetaxel 1Cisplatin 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Locally Advanced Non-small Cell Lung Cancer × Immunotherapy × Clear all
NCT05481775 2022-11-21

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Sun Yat-sen University

Phase 2 Withdrawn
Thoracic

Locally Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡